Tagomics Partners with Agilent Technologies to Revolutionize Multiomic Biomarker Discovery

Bio-Techne Partners with Leader Life Sciences to Expand in the GCC Region

Owkin and Proscia Partner to Revolutionize MSI Testing for Colorectal Cancer with AI-Powered Solutions

Telix Expands Theranostic Pipeline with FAP-Targeting Radiopharmaceuticals

Alamar Biosciences and The Michael J. Fox Foundation Partner to Advance Parkinson’s Disease Biomarker Discovery

Stilla Technologies Partners with Source BioScience to Advance Genomics in the UK and Ireland

Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® in NSCLC

Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

Home
/
med-marvels
/
details

Successful Treatment of Advanced Prostate Cancer at American Oncology Institute (AOI) in Hyderabad

NextEdge Admin

31 Jul 2024

3 min 21 sec

The American Oncology Institute,immunotherapy,Oncology

The American Oncology Institute (AOI) at Citizens Specialty Hospital in Hyderabad is pleased to announce the successful treatment of a 72-year-old male patient with advanced prostate cancer. The patient, who initially experienced acute urinary retention in 2014, consulted a urologist and was diagnosed with prostate carcinoma after a biopsy. He underwent bilateral orchidectomy and received multiple lines of chemotherapy at different hospitals, experiencing several relapses.

In 2022, the patient returned to AOI with a recurrence of the disease but surprisingly low PSA levels. The doctors at AOI decided to perform a repeat biopsy, which revealed a transitional cell variant of prostate carcinoma. Considering the patient’s age, frailty, and extensive prior treatments, the medical team conducted next-generation sequencing on the tumor tissue, which showed MSI high and TMB high status, warranting immunotherapy.

Dr. K.V. Krishnamani, Medical Oncologist at AOI, explained the multidisciplinary approach: "The advanced nature of the patient's cancer required a combination of molecular testing and immunotherapy. This comprehensive strategy not only addressed the cancer but also significantly improved the patient's quality of life. His response to the treatment has been very encouraging, showcasing AOI's advanced care capabilities."

The patient received immunotherapy every three weeks, and now, two years from the start of this treatment, his disease is in complete remission. He is clinically well, ambulatory, and in much better health than he was in 2022. This case highlights the necessity of specialized molecular testing, the importance of repeat biopsies in recurrence cases, and the excellent results achievable with immunotherapy in such patients.

Harish Trivedi, CEO of CTSI-South Asia, emphasized the importance of leveraging cutting-edge diagnostics and personalized medicine in cancer treatment. Dr. Prabhakar P, Regional COO of AOI, highlighted AOI's commitment to integrating advanced technology with expert clinical knowledge to provide personalized treatment plans.

Dr. Krishnamani also stressed the importance of regular screenings for early detection of prostate cancer, which significantly improves treatment outcomes. He encourages all men over 50 and those with a family history of the disease to undergo routine check-ups and screenings.